Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$131.95 +3.1%	$129.84	$110.04 ▼ $213.50	$18.76B	0.13	1.27 million shs	2.80 million shs
IONS Ionis Pharmaceuticals	$43.03 +0.1%	$39.07	$23.95 ▼ $50.43	$6.86B	0.25	1.75 million shs	2.32 million shs
NBIX Neurocrine Biosciences	$128.91 +0.5%	$128.26	$84.23 ▼ $157.40	$12.69B	0.24	901,206 shs	1.40 million shs
UTHR United Therapeutics	$294.28 +7.1%	$298.13	$266.98 ▼ $417.82	$12.39B	0.57	426,182 shs	2.43 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+3.09%	+0.33%	-0.93%	+6.82%	-38.11%
IONS Ionis Pharmaceuticals	+0.12%	+1.87%	-1.28%	+31.27%	-13.00%
NBIX Neurocrine Biosciences	+0.53%	-2.44%	-0.38%	+17.53%	-8.94%
UTHR United Therapeutics	+7.13%	-3.36%	-0.32%	-0.11%	-6.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.8441 of 5 stars	4.2	4.0	3.7	3.3	2.5	1.9
IONS Ionis Pharmaceuticals	4.5202 of 5 stars	4.4	3.0	3.0	3.2	2.5	0.6
NBIX Neurocrine Biosciences	4.6866 of 5 stars	3.4	5.0	2.9	3.3	2.5	1.9
UTHR United Therapeutics	4.9622 of 5 stars	4.3	3.0	4.6	3.8	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.34	Hold	$185.63	40.68% Upside
IONS Ionis Pharmaceuticals	2.86	Moderate Buy	$59.38	38.01% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$160.90	24.82% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$379.69	29.02% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, UTHR, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$125.00 ➝ $135.00
8/1/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$208.00 ➝ $219.00
8/1/2025	BIIB Biogen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$146.00 ➝ $144.00
8/1/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$187.00 ➝ $194.00
8/1/2025	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$165.00 ➝ $175.00
7/31/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$425.00 ➝ $400.00
7/31/2025	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$60.00 ➝ $64.00
7/31/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00
7/31/2025	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $62.00
7/31/2025	NBIX Neurocrine Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$140.00 ➝ $145.00
7/31/2025	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$150.00 ➝ $158.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.00	$23.82 per share	5.54	$120.35 per share	1.10
IONS Ionis Pharmaceuticals	$944.05M	7.27	N/A	N/A	$3.96 per share	10.87
NBIX Neurocrine Biosciences	$2.51B	5.08	$3.40 per share	37.94	$27.17 per share	4.74
UTHR United Therapeutics	$2.88B	4.61	$30.43 per share	9.67	$159.04 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	12.61	7.99	1.85	15.31%	13.85%	8.32%	N/A
IONS Ionis Pharmaceuticals	-$453.90M	-$1.84	N/A	N/A	N/A	-28.25%	-45.29%	-8.99%	N/A
NBIX Neurocrine Biosciences	$341.30M	$3.38	38.14	19.92	1.32	13.88%	13.22%	9.39%	N/A
UTHR United Therapeutics	$1.20B	$25.06	11.49	10.70	5.97	40.36%	18.73%	16.49%	N/A

Latest IONS, BIIB, UTHR, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	$0.70	+$0.51	$0.70	$270.90 million	$452.00 million
7/30/2025	Q2 2025	NBIX Neurocrine Biosciences	$0.98	$1.06	+$0.08	$1.06	$653.09 million	$687.50 million
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.80	$6.41	-$0.39	$6.41	$802.13 million	$798.60 million
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.36	2.50	1.01
IONS Ionis Pharmaceuticals	0.99	2.87	9.62
NBIX Neurocrine Biosciences	N/A	3.20	3.02
UTHR United Therapeutics	N/A	7.26	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
IONS Ionis Pharmaceuticals	93.86%
NBIX Neurocrine Biosciences	92.59%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
IONS Ionis Pharmaceuticals	2.60%
NBIX Neurocrine Biosciences	4.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.39 million	155.02 million	Optionable
NBIX Neurocrine Biosciences	1,800	98.97 million	94.22 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

IONS, BIIB, UTHR, and NBIX Headlines

Recent News About These Companies

BTIG Sticks to Their Hold Rating for United Therapeutics (UTHR)

1 hour ago | theglobeandmail.com

United Therapeutics Corporation (NASDAQ:UTHR) Short Interest Up 2,016.4% in July

1 hour ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Stock Price Up 4.9% - Here's Why

4 hours ago | marketbeat.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for UTHR

August 2 at 6:23 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Natixis Advisors LLC

August 2 at 5:38 AM | marketbeat.com

3,108 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by GSA Capital Partners LLP

August 2 at 5:20 AM | marketbeat.com

United Therapeutics (UTHR) Launches $1 Billion Share Buyback

August 1 at 12:11 AM | gurufocus.com

United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $295.00 at Wells Fargo & Company

August 1 at 1:05 PM | marketbeat.com

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study

August 1 at 12:41 PM | tipranks.com

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment

August 1 at 12:41 PM | tipranks.com

United Therapeutics enters $1B accelerated share repurchase program

August 1 at 8:21 AM | msn.com

Cozad Asset Management Inc. Acquires Shares of 1,805 United Therapeutics Corporation (NASDAQ:UTHR)

August 1 at 5:23 AM | marketbeat.com

Forecasting The Future: 8 Analyst Projections For United Therapeutics

July 31 at 4:16 PM | benzinga.com

UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y

July 31 at 11:16 AM | zacks.com

United Therapeutics (UTHR) Price Target Lowered by HC Wainwright & Co. | UTHR Stock News

July 31 at 8:12 AM | gurufocus.com

Optimistic Buy Rating for United Therapeutics Driven by Promising TETON Trial Prospects for Tyvaso in IPF Market

July 31 at 6:23 AM | tipranks.com

Earnings Summary on United Therapeutics

July 31 at 2:23 AM | fool.com

United Therapeutics Reports Record Q2 2025 Financial Results

July 30 at 12:31 AM | tipranks.com

United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call Transcript

July 30 at 11:02 PM | seekingalpha.com

MannKind’s Growth Potential Bolstered by United Therapeutics Partnership and Promising Pipeline

July 30 at 3:50 PM | tipranks.com

United Therapeutics: Strong Growth Potential and Strategic Moves Justify Buy Rating

July 30 at 3:50 PM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
By Leo Miller | July 29, 2025
View Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows

IONS, BIIB, UTHR, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

$131.95 +3.95 (+3.09%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$132.24 +0.29 (+0.22%)

As of 08/1/2025 07:59 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Ionis Pharmaceuticals NASDAQ:IONS

$43.03 +0.05 (+0.12%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$42.98 -0.05 (-0.10%)

As of 08/1/2025 07:23 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Neurocrine Biosciences NASDAQ:NBIX

$128.91 +0.68 (+0.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$124.56 -4.35 (-3.38%)

As of 08/1/2025 06:44 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$294.28 +19.58 (+7.13%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$294.42 +0.15 (+0.05%)

As of 08/1/2025 07:26 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time